kellendonk-335x470

Associate Professor of Pharmacology in Psychiatry
Columbia University
New York State Psychiatric Institute

1051 Riverside Drive
Kolb Annex, 3rd floor
New York, NY 10032
646-774-8602
ck491@cumc.columbia.edu

Faculty Profile

Neuroscience PhD

Research Summary

My laboratory uses mouse genetic tools in an effort to understand the biology that underlies the symptoms of schizophrenia. Schizophrenia is characterized by three symptom clusters: the so-called cognitive, negative and positive symptoms. While the positive symptoms – which include disordered thought processes, hallucinations and delusions – are the most characteristic feature of the disorder, such symptoms are more difficult to model in the mouse. In contrast, the cognitive and negative symptoms of the disorder – including deficits in working memory and motivation – have behavioral readouts homologous to humans in mouse models. Such mouse models are therefore very useful to study the biological underpinnings of deficits in these behaviors. This is important because cognitive and negative symptoms of the disorder are poorly understood but are particularly difficult to treat. Not only do these symptoms dramatically affect day-to-day functioning, they are largely intractable to antipsychotic medications targeting the dopamine D2 receptor, which only ameliorate the positive symptoms of the disorder. As such, the severity of cognitive and negative symptoms is a better predictor for the long-term prognosis of patients than the degree of positive symptoms. It is important to note however, that deficits in working memory and motivation are not specific to schizophrenia, but are also present in other mental disorders such as depression and ADHD. In this context, the work in my laboratory has broader applications, revealing both normal and aberrant brain function relevant to mental disorders characterized by deficits in cognitive and motivational behaviors.

To tie this research closely to disease-relevant brain circuitry, our approach uses observations made in patients with schizophrenia and then seeks to “model” these observations as closely as possible in the mouse. This allows for determining how an alteration can cause changes in brain function and behavior – a major limitation of human studies where findings are by and large correlational. Using this approach we hope to achieve three main goals:

  • To better understand the basic mechanisms that regulate cognitive and motivated behaviors relevant for schizophrenia
  • To inspire new human studies based on outcomes from our mouse models
  • To develop new treatment strategies for enhancing cognition and motivation
Select Publications
  1. Bolkan S., Stujenske J.M., Parnaudeau S., Spellman T.J, Rauffenbart C., Abbas A., Harris A.Z., Gordon J.A., Kellendonk C. (2017) Thalamic projections sustain prefrontal activity during working memory maintenance Nature Neuroscience 20(7):987-996.
  2. Carvalho Poyraz F., Holzner E., Bailey M.R., Meszaros J., Kenney L., Kheirbek M.A., Balsam P.D., Kellendonk C.(2016) Decreasing striato-pallidal pathway function enhances motivation by energizing the initiation of goal directed action J. Neuroscience 36(22):5988-6001
  3. Canetta S., Bolkan S., Padilla-Coreano N., Song L.J., Sahn R., Harrison N.L., Gordon J.A., Brown A., Kellendonk C. (2016) Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons. Molecular Psychiatry 21(7):956-68
  4. Gallo E.F., Salling M.C., Feng B., Morón J.A., Harrison N.L., Javitch J.A., Kellendonk C. (2015) Upregulation of dopamine D2 receptors in the nucleus accumbens indirect pathway increases locomotion but does not reduce alcohol consumption. Neuropsychopharmacology 40:1609-18.
  5. Parnaudeau S, Taylor K, Bolkan SS, Ward RD, Balsam PD, Kellendonk C. (2015) Mediodorsal thalamus hypofunctionimpairs flexible goal-directed behavior. Biological Psychiatry. 77:445-453.
  6. Cazorla M, de Carvalho FD, Chohan MO, Shegda M, Chuhma N, Rayport S, Ahmari SE, Moore H, Kellendonk C.(2014) Dopamine D2 receptors regulate the anatomical and functional balance of basal ganglia circuitry. Neuron. 81:153-164.
  7. Parnaudeau S, O’Neill PK, Bolkan SS, Ward RD, Abbas AI, Roth BL, Balsam PD, Gordon JA, Kellendonk C.(2013) Inhibition of mediodorsal thalamus disrupts thalamofrontal connectivity and cognition. Neuron. 77:1151-1162.
  8. Cazorla M, Shegda M, Ramesh B, Harrison NL, Kellendonk C. (2012) Striatal D2 receptors regulate dendritic morphology of medium spiny neurons via Kir2 channels. J Neuroscience. 32:2398-2409.
Grants
  1. 05/2011-09/2021         “Functionally selective D2Rs, striatal circuitry and motivation” NIMH RO1 MH093672 (Kellendonk, PI)
  2. 01/2014-12/2019         “Identifying neuronal circuits and mechanisms of working memory” Irma T. Hirschl Research Awards (Kellendonk, PI)
  3. 07/2017-06/2019         “The role of thalamic dopamine D2 receptors in cocaine intake” NIDA R21 DA044329 (Kellendonk, PI)

Return to Members